IceCure Medical (ICCM) Expected to Announce Earnings on Thursday

IceCure Medical (NASDAQ:ICCM) is projected to issue its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $1.3440 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 11:00 AM ET.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings data on Sunday, February 15th. The company reported $0.06 earnings per share (EPS) for the quarter. The business had revenue of $1.28 million during the quarter. IceCure Medical had a negative net margin of 445.61% and a negative return on equity of 221.04%. On average, analysts expect IceCure Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

IceCure Medical Trading Down 6.6%

NASDAQ ICCM opened at $0.27 on Thursday. The company has a fifty day simple moving average of $0.46 and a 200 day simple moving average of $0.60. The company has a market cap of $21.59 million, a P/E ratio of -1.11 and a beta of 0.47. IceCure Medical has a 1 year low of $0.25 and a 1 year high of $1.40.

Hedge Funds Weigh In On IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Jane Street Group LLC acquired a new stake in IceCure Medical Ltd. (NASDAQ:ICCM) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 109,638 shares of the company’s stock, valued at approximately $67,000. Jane Street Group LLC owned approximately 0.16% of IceCure Medical as of its most recent filing with the SEC. 0.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ICCM has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a report on Tuesday, April 21st. Alliance Global Partners initiated coverage on shares of IceCure Medical in a report on Monday. They set a “buy” rating for the company. Finally, Wall Street Zen raised shares of IceCure Medical from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, IceCure Medical presently has an average rating of “Hold” and an average price target of $2.64.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.